Arrowhead's plozasiran hits primary endpoint in Phase 3 SHASTA-3 and SHASTA-4
Arrowhead Pharmaceuticals (NASDAQ: ARWR) reported positive topline results on 22 July 2026 from its global Phase 3 SHASTA-3 and SHASTA-4 studies of plozasiran, an RNAi therapeutic, in patients with severe hypertriglyceridemia (sHTG) — a condition that sharply raises the risk of acute pancreatitis.
Both studies met their primary endpoint of triglyceride reduction versus placebo and all prespecified secondary endpoints. Plozasiran 25 mg, given as a subcutaneous injection once every three months, produced median triglyceride reductions of 79% (SHASTA-3) and 81% (SHASTA-4) at month 12, versus roughly 27% on placebo. A pre-planned pooled analysis showed a statistically significant reduction in acute pancreatitis events, including a 78% reduction in cumulative events across the broad sHTG population and a 100% event reduction in the highest-risk subset (triglycerides above 880 mg/dL with a prior history of acute pancreatitis). No new safety signals were observed.
Arrowhead said it plans to file a supplemental New Drug Application (sNDA) in the United States before the end of 2026, with additional global submissions to follow. Detailed results will be presented as a HOT LINE Late Breaker at the European Society of Cardiology (ESC) Congress on 30 August 2026.